Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,654.60on 22-07-2019 at 16:30:00
Change 8.20 0.50%
Buy 1,653.20
Sell 1,652.60
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 502 at 1,653.437p
Day's Volume: 4,672,640
Last Close: 1,646.40p
Open: 1,646.40p
ISIN: GB0009252882
Day's Range 1,639.20p - 1,662.00p
52wk Range: 1,408.80p - 1,672.00p
Market Capitalisation: £81,837m
VWAP: 1,653.751p
Shares in Issue: 4,946m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy*5021,653.437Ordinary
Delayed publication
18:28:10 - 22-Jul-19
Buy*72,0191,654.71517:50:42 - 22-Jul-19
Sell*1,4391,651.99417:42:32 - 22-Jul-19
Buy*21,3711,656.77117:40:38 - 22-Jul-19
Sell*6141,651.598Ordinary
Delayed publication
17:40:33 - 22-Jul-19
Sell*33,9401,646.4017:05:15 - 22-Jul-19
Buy*1021,653.86517:26:14 - 22-Jul-19
Sell*156,5691,646.4017:05:15 - 22-Jul-19
Buy*17,7731,653.03017:09:12 - 22-Jul-19
Buy*24,9061,652.96517:09:12 - 22-Jul-19

Share Price History for Glaxosmithkline

Time period:
to
Frequency:
Date Open High Low Close Volume
19th Jul 2019 (Fri)1,654.001,662.401,639.001,649.807,480,572
18th Jul 2019 (Thu)1,650.001,660.001,645.201,660.605,335,749
17th Jul 2019 (Wed)1,666.001,669.801,653.201,665.006,530,554
16th Jul 2019 (Tue)1,646.601,672.001,645.401,638.6010,511,603
15th Jul 2019 (Mon)1,618.001,643.401,614.401,623.805,853,570
12th Jul 2019 (Fri)1,633.201,634.201,615.001,632.406,155,355
11th Jul 2019 (Thu)1,649.001,658.001,627.801,643.209,830,351
10th Jul 2019 (Wed)1,637.001,646.001,628.201,640.205,667,811
9th Jul 2019 (Tue)1,622.201,643.401,622.201,628.006,270,497
8th Jul 2019 (Mon)1,629.801,631.801,619.801,636.609,833,159
5th Jul 2019 (Fri)1,636.801,645.801,628.401,639.005,096,604
4th Jul 2019 (Thu)1,637.801,645.201,635.801,641.203,277,522
3rd Jul 2019 (Wed)1,625.001,651.001,617.201,620.208,177,549
2nd Jul 2019 (Tue)1,600.001,620.201,591.601,590.409,072,995
1st Jul 2019 (Mon)1,594.801,602.601,581.601,576.606,180,692
28th Jun 2019 (Fri)1,581.801,583.601,570.401,582.005,385,995
27th Jun 2019 (Thu)1,587.801,587.801,564.801,587.205,234,774
26th Jun 2019 (Wed)1,601.401,604.401,581.201,605.608,233,723
25th Jun 2019 (Tue)1,587.401,608.601,581.001,593.005,377,881
24th Jun 2019 (Mon)1,577.601,597.801,572.401,576.4010,206,599

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

GlaxoSmithKline Admits Employees Broke The Law In China

News - Monday, July 22, 2019

The head of emerging markets at GlaxoSmithKline, Abbas Hussain, has issued a statement admitting that employees had acted in breach of Chinese Law and stating that the company will review the way it operated in China, amidst a corruption and bribery scandal....

FTSE Gains as Insurers Boosted

News - Monday, July 22, 2019

The FTSE 100 climbed on Wednesday after insurers posted a positive performance, noting signs of a rebound in car premiums. Another major gainer was GlaxoSmithKline, who published better-than-expected results for the last quarter....

FTSE 100 Latest
Value7,514.93
Change6.23


Login to your account

Forgot Password?

Not Registered